AI Governance for Private GP and GP-Led Clinics

Why private GP clinics are ELSA AI's primary audience

Private GP clinics sit at the intersection of four pressures.

1. 1. CQC-regulated clinical activity

   GP services are assessed against CQC's key questions, including whether a service is safe and well-led. Where AI affects clinical records, care workflows, data processing or human oversight, the clinic needs a documented position it can show.

2. 2. GP-specific AI inspection signals

   CQC's GP Mythbuster 109, "Use of artificial intelligence (AI) in GP services," is GP-specific guidance. It sets out expectations around clinical risk management, a named Clinical Safety Officer where the DCB0160 deployer standard applies, documented risk assessment, human oversight of AI outputs, supplier due diligence at the point of procurement, and patient transparency including the ability to object. It is a clear governance-standard signal for GP providers. It is not a substitute for the clinic's own legal, regulatory or clinical safety review.

3. 3. High-volume special category health data

   GP consultations generate sensitive clinical information at volume. AI tools that process consultation audio, notes, correspondence, images, summaries or patient identifiers need DPIA screening. In many cases a DPIA is likely required or strongly indicated, with DPO or legal review needed where processing is likely high risk. That determination is the clinic's DPO's to make, not ELSA AI's.

4. 4. Insurer, MDO and PMI scrutiny

   AI use may become relevant to insurer, PMI or MDO questions, particularly where tools affect clinical documentation, patient communication, consultation recording, diagnosis, triage or professional accountability. The consistent theme across medical defence organisation guidance is that the clinician remains responsible for the accuracy of the clinical record, including where the first draft was AI-generated, and that AI use outside organisational approval and governance may carry personal risk. The current position should be confirmed with your own MDO.

The typical governance position we find

In private GP and GP-led clinics, the recurring pattern is an evidence gap rather than a single catastrophic failure.

Common findings include:

• AI is in use, but there is no single inventory of tools, users, purposes or patient-data exposure.
• There is no AI-specific policy distinguishing approved, conditional and prohibited use.
• Ambient scribe or transcription use has started before the DPIA workpack is ready for DPO review.
• Vendor evidence is incomplete or scattered across email, procurement files and individual clinicians.
• Staff have not received a clear written position on ChatGPT, Copilot, transcription tools or personal-device AI.
• There is no documented board or partnership view of AI risk.
• Incident reporting does not explicitly cover AI-related issues such as inaccurate or fabricated notes, transcription errors or unintended disclosure.

None of this is a legal conclusion. It means there is an evidence gap. That gap becomes urgent when a DPO, insurer, MDO, CQC inspector, board member or patient asks how AI use is controlled.

Common triggers for engaging ELSA AI

• CQC inspection scheduled or anticipated.
• Insurer or PMI renewal questionnaire including AI questions.
• DPO requesting evidence on AI processing of patient data.
• Ambient scribe rollout under consideration, in pilot or already live.
• MDO query following an incident, complaint or routine review.
• Board, partnership or investor AI review.
• Staff, patient or referrer concern about AI use.
• Microsoft Copilot, ChatGPT or transcription tools appearing in workflows without a documented policy.

Fee and timeline

Fixed fee: £5,500 + VAT. Delivered within four working days from the start of delivery.

This standard fixed fee covers a single-site GP or GP-led clinic of up to 60 staff, in a single clinical specialty, with no NHS contract or NHS data-sharing arrangement in scope. Larger clinics, multiple sites or mixed specialties are scoped individually.

Where an ambient scribe, AI transcription or note-generation tool is in use, in trial or planned, the engagement routes to the Clinical AI Exposure Diagnostic™ with Ambient Scribe Assessment at £8,500 + VAT, delivered in six working days.

A separate six-working-day engagement. The ambient scribe assessment runs through the full evidence pack, not as a standalone addition.

View pricing details

No platform subscription. No retainer required to start.

For clinics that want to convert the Diagnostic into a board-adopted governance baseline, the Clinical AI Safe Usage Launchpad™ follows over four to six weeks. For clinics that want their governance evidence kept current as tools, staff use, vendor terms and regulatory expectations change, the AI Exposure Sentinel™ retainer is available at £950 per month, £2,850 per quarter in advance, or £10,500 per year prepaid, + VAT. Annual prepaid is preferred.

Founder-delivered

Engagements are led by Faisal Ali, AAISM, CISM, CRISC, Founder and Principal Consultant of ELSA AI. Faisal brings more than two decades in cybersecurity, information risk and governance across healthcare, financial services and national infrastructure.

Senior-led. No junior delegation. No template-and-invoice model.